Patents by Inventor Jeffrey A. Pfefferkorn

Jeffrey A. Pfefferkorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINYL GLUCAGON RECEPTOR MODULATORS
    Publication number: 20150353508
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: August 19, 2015
    Publication date: December 10, 2015
    Applicant: PFIZER INC.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • Quinolinyl glucagon receptor modulators
    Patent number: 9139538
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: September 22, 2015
    Assignee: Pfizer Inc.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • QUINOLINYL GLUCAGON RECEPTOR MODULATORS
    Publication number: 20150099882
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 9, 2015
    Applicant: Pfizer Inc.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • Quinolinyl glucagon receptor modulators
    Patent number: 8927577
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: January 6, 2015
    Assignee: Pfizer Inc.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • QUINOLINYL GLUCAGON RECEPTOR MODULATORS
    Publication number: 20140135338
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: July 12, 2012
    Publication date: May 15, 2014
    Applicant: PFIZER INC.
    Inventors: Mary Didiuk, Kevin J. Filipski, Angel Guzman-Perez, Esther C. Lee, Jeffrey A. Pfefferkorn, Benjamin Stevens, Meihua Tu
  • Substituted Indazole Amides And Their Use As Glucokinase Activators
    Publication number: 20110319379
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R4, R6, X, Y and Z are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 29, 2011
    Inventors: Jeffrey W. Corbett, Angel Guzman-Perez, Jeffrey A. Pfefferkorn, Meihua Tu
  • NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS
    Publication number: 20090170852
    Abstract: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
    Type: Application
    Filed: October 8, 2008
    Publication date: July 2, 2009
    Inventors: Chulho Choi, Daniel Merritt Bowles, Richard H. Hutchings, William K.C. Park, Jeffrey A. Pfefferkorn
  • Pyrazole-based HMG CoA reductase inhibitors
    Patent number: 7446121
    Abstract: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: November 4, 2008
    Assignee: Pfizer Inc.
    Inventor: Jeffrey A. Pfefferkorn
  • Novel Substituted Azetidinones
    Publication number: 20080227974
    Abstract: Novel azetidinones and pharmaceutical compositions are described, as are the methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis.
    Type: Application
    Filed: July 20, 2006
    Publication date: September 18, 2008
    Inventors: Jeffrey A. Pfefferkorn, Bharat K. Trivedi
  • Inhibitors of NADH:ubiquinone oxidoreductase
    Patent number: 7410998
    Abstract: Benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase for inhibiting the growth of cancer cells.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: August 12, 2008
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Jeffrey Pfefferkorn, Guo-Qiang Cao, Anthony Roecker
  • Novel pyrazole-based HMG CoA reductase inhibitors
    Publication number: 20060111422
    Abstract: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
    Type: Application
    Filed: November 18, 2005
    Publication date: May 25, 2006
    Inventors: Chulho Choi, Daniel Bowles, Richard Hutchings, William Park, Jeffrey Pfefferkorn
  • Inhibitors of HCV NS5B polymerase
    Patent number: 7041690
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 9, 2006
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Barry Craig Finzel, Hua Gao, Meredith L. Greene, Rebecca J. Gross, Richard Allen Nugent, Jeffrey A. Pfefferkorn
  • Inhibitors of HCV NS5B polymerase
    Publication number: 20060004063
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
    Type: Application
    Filed: August 9, 2005
    Publication date: January 5, 2006
    Inventors: Barry Finzel, Hua Gao, Meredith Greene, Rebecca Gross, Richard Nugent, Jeffrey Pfefferkorn
  • N-alkyl pyrroles as HMG-CoA reductase inhibitors
    Publication number: 20050154042
    Abstract: HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.
    Type: Application
    Filed: December 2, 2004
    Publication date: July 14, 2005
    Inventors: Larry Bratton, Xue-Min Cheng, Chitase Lee, Steven Miller, Jeffrey Pfefferkorn, Toni-Jo Poel, Roderick Sorenson, Yuntao Song, Kuai-Lin Sun, Bharat Trivedi, Paul Unangst
  • Inhibitors of HCV NS5B polymerase
    Publication number: 20050154056
    Abstract: The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment and prevention of hepatitis C virus (HCV) infection. In particular, the present invention provides novel compounds, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment or prevention of HCV infection. The present invention also provides processes and intermediates for the synthesis of these compounds.
    Type: Application
    Filed: November 3, 2004
    Publication date: July 14, 2005
    Inventors: Fan Yang, Bo Zhang, Nancy Wicnienski, Jeffrey Pfefferkorn, Meredith Greene, Ke Chen, Richard Nugent, Matthew Reding, Robert Kelly, Mark Mitchell, Lee Funk, Richard Heier, Rebecca Anderson
  • Inhibitors of HCV NS5B polymerase
    Publication number: 20040142980
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
    Type: Application
    Filed: June 30, 2003
    Publication date: July 22, 2004
    Inventors: Barry Craig Finzel, Hua Gao, Meredith L. Greene, Rebecca J. Gross, Richard Allen Nugent, Jeffrey A. Pfefferkorn
  • Inhibitors of nadh:ubiquinone oxidoreductase
    Publication number: 20040034239
    Abstract: Novel benzopyran-based inhibitors of NADH:ubiquinone oxidoreductase are designed, synthesized, and shown to have anti-cancer activity.
    Type: Application
    Filed: July 23, 2003
    Publication date: February 19, 2004
    Inventors: Kyriacos C Nicolaou, Jeffrey Pfefferkorn, Guo-Qiang Cao, Anthony Roecker